Nuvera Biosciences Licenses PGx Assays to Veridex | GenomeWeb

NEW YORK (GenomeWeb News) – Nuvera Biosciences has licensed pharmacogenomic assays that it has developed to Veridex, which will commercialize the tests.

The multi-gene assays were developed for predicting patient response to tamoxifen therapy and taxane-containing chemotherapy in breast cancer. Woburn, Mass.-based Nuvera developed the assays in collaboration with the University of Texas MD Anderson Cancer Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.